Ajani J A, Baker F L, Spitzer G, Kelly A, Brock W, Tomasovic B, Singletary S E, McMurtrey M, Plager C
Department of Medical Oncology, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston 77030.
J Clin Oncol. 1987 Dec;5(12):1912-21. doi: 10.1200/JCO.1987.5.12.1912.
The newly described adhesive tumor cell culture system (ATCCS) offers a distinct advantage over other assays in that it has a high plating efficiency requiring low cell inoculum, it affords workable assays in approximately 70% of specimens from the heterogenous tumor types, and it has the ability to assay up to nine drugs at four different concentrations. Clinical correlations based on the ATCCS were obtained in 65 patients undergoing 71 clinical trials. Patients with melanoma, lung cancer, and sarcoma dominated the group. The most active in vitro drug was correlated per clinical trial. Thirteen of 17 (76%) sensitive in vitro predictions and 51 of 54 (94%) resistant in vitro predictions were accurate. The assay in this study had a sensitivity of 81% and specificity of 93%. These preliminary results are encouraging and warrant prospective trials to establish the true value of this assay to patients.
新描述的黏附肿瘤细胞培养系统（ATCCS）相对于其他检测方法具有明显优势，即其接种效率高，所需细胞接种量低，在大约70%的异质性肿瘤类型标本中能提供可行的检测，并且能够在四个不同浓度下检测多达九种药物。基于ATCCS的临床相关性在65例接受71项临床试验的患者中得到了验证。该组患者以黑色素瘤、肺癌和肉瘤患者为主。每次临床试验中都将体外活性最强的药物与之相关联。17项体外敏感预测中有13项（76%）以及54项体外耐药预测中有51项（94%）是准确的。本研究中的检测方法灵敏度为81%，特异性为93%。这些初步结果令人鼓舞，值得进行前瞻性试验以确定该检测方法对患者的真正价值。
